Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
|Articles|June 1, 2002
- Pharmaceutical Technology-06-02-2002
- Volume 26
- Issue 6
Microencapsulation of Paracetamol by Various Emulsion Techniques Using Cellulose Acetate Phthalate
Author(s)Ali Nokhodchi, PharmD, PhD
Three methods for microencapsulating paracetamol using cellulose acetate phthalate as the coating agent revealed significant differences in terms of drug content, microcapsule size, and drug release rate.
Advertisement
Articles in this issue
over 24 years ago
Excipient GMP Quality Standards: One is Enoughover 24 years ago
The IPEC-Americas Excipient Master File Guideover 24 years ago
Technology Advances Anticounterfeiting Optionsover 24 years ago
Calibration of Lyophilization Pressure Gaugesover 24 years ago
Drug Shortages Reveal GMP Concernsover 24 years ago
Outsourcing Outlookover 24 years ago
Optimizing Cross-Organizational Team Performance and Managementover 24 years ago
Screening for Counterfeit Drugs Using Near-Infrared Spectroscopyover 24 years ago
Building on Tradition: Integrating the Links of ExpertiseAdvertisement
Related to this article
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Vibha Jawa, PhD, chief scientific officer at EpiVax, discusses the limitations of current preclinical testing approaches and how new approach methodologies can strengthen drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA/CMS Gene Editing Guidance Shifts Evidence to CMC Teams
2
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
3
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5